# Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

> **NCT00254735** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Obsessive Compulsive Disorder

## Interventions

- **DRUG:** quetiapine fumarate
- **DRUG:** SSRI/Clomipramine

## Key facts

- **NCT ID:** NCT00254735
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2007-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254735, "Quetiapine Augmentation in Severe Obsessive Compulsive Disorder". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00254735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*